SSRX Share Price

Open 16.61 Change Price %
High 16.64 1 Day 0.00 0.00
Low 16.59 1 Week 0.00 0.00
Close 16.59 1 Month 0.00 0.00
Volume 253819 1 Year 0.00 0.00
52 Week High 15.84
52 Week Low 7.70
SSRX Important Levels
Resistance 2 16.64
Resistance 1 16.62
Pivot 16.61
Support 1 16.56
Support 2 16.54
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TOPS 0.44 69.23%
SCHS 0.05 66.67%
ELTK 0.95 53.23%
LOCM 0.09 50.00%
SGMS 34.15 27.19%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
MTSL 0.64 20.75%
WBMD 66.10 19.77%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
CYTX 0.48 -56.76%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

3SBio Inc. (NASDAQ: SSRX)

SSRX Technical Analysis 5
As on 29th May 2013 SSRX Share Price closed @ 16.59 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 13.73 & Strong Buy for SHORT-TERM with Stoploss of 15.80 we also expect STOCK to react on Following IMPORTANT LEVELS.
SSRX Target for July
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SSRX Other Details
Segment EQ
Market Capital 295193888.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SSRX Address
SSRX
N/A
SSRX Latest News
Interactive Technical Analysis Chart 3SBio Inc. ( SSRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on 3SBio Inc.
SSRX Business Profile
3SBio Inc. is a biotechnology company in the People's Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.